Yaqi Ren, Chunlan Wang, Jiakun Xu, Shuaiyu Wang
8 min
Coffee contains various bioactive compounds, among which cafestol and kahweol are notable natural diterpenes. These compounds are particularly abundant in unfiltered coffee, such as Turkish or French-press brews, as they are often removed during the filtration process. This paper reviews the complex biological roles of these two diterpenes, which act as double-edged swords by negatively impacting lipid profiles while simultaneously demonstrating multi-target therapeutic potential in various pathological states.
One of the most well-documented effects of cafestol and kahweol is their ability to increase serum lipid levels. Long-term consumption of unfiltered coffee is associated with higher plasma triacylglycerol and LDL cholesterol. Cafestol appears to be the primary driver of this effect, largely by suppressing the activity of the LDL receptor pathway and downregulating enzymes involved in bile acid synthesis. While this represents a potential risk factor for cardiovascular disease, the compounds' influence on other metabolic pathways suggests a more nuanced interaction with human health.
Beyond their impact on lipid metabolism, cafestol and kahweol exhibit several beneficial bioactivities:
The dual nature of cafestol and kahweol makes them interesting candidates for nutritional intervention and pharmaceutical development. Understanding the precise mechanisms—and how the slight structural difference of an extra conjugated double bond in kahweol affects its potency compared to cafestol—is crucial for harnessing their benefits while managing the risks of lipid elevation. This research supports the ongoing evaluation of coffee diterpenes as multi-target functional food components.
Sam: Now take us to the proposed benefits. What makes the anti-inflammatory evidence more than a collection of lower chemical readings?
Alex: One useful example involves macrophages, immune cells that produce inflammatory signals. Researchers stimulated cultured mouse macrophages with a bacterial component, then tested the coffee compounds. Both compounds reduced production of inflammatory mediators, and the experiments also traced changes in the machinery producing them.
Sam: A compound could lower those readings simply by damaging the cells. Did the studies distinguish that from suppressing inflammation?
Alex: In the experiment described, cell viability remained high. The compounds reduced both the gene messages and the protein levels of enzymes that make the inflammatory mediators. That supports a regulated response rather than simply fewer living cells, although it remains a cultured-cell result.
Sam: The distinction matters: there is a proposed causal chain, not just an endpoint. How far upstream did the researchers trace it?
Alex: The review highlights inhibition of a signaling switch called nuclear factor kappa B, which helps activate inflammatory genes. Other experiments point to different targets for each compound. Cafestol affected another gene-control pathway, while kahweol affected signaling involved in inflammatory responses.
Sam: Multiple targets can sound attractive, but they can also make interpretation messy. Does the review identify one mechanism that explains everything?
Alex: It does not. Its central picture is overlapping actions, not a single master target. Some proposed steps remain unresolved. There is also animal support for anti-inflammatory activity, including kahweol in an acute rat inflammation model, but that is not evidence of treating chronic inflammatory disease in people.
Sam: Let’s turn to cancer. That label covers very different claims, from preventing damage to killing an established tumour. Which does this review actually cover?
Alex: It separates those stages. First, the compounds may reduce activation of certain cancer-causing chemicals and increase detoxification defenses. Second, experiments examine whether they trigger apoptosis, meaning programmed cell death, in cancer cells. Third, researchers test angiogenesis, the formation of new blood vessels that can support tumour growth.
Sam: Those are distinct experimental questions. What is a concrete example from the cell-death work?
Alex: In a kidney cancer cell line, cafestol reduced proteins that protect cells from death and activated parts of the cell-death machinery. Other experiments found stronger cancer-cell killing when cafestol or kahweol was combined with particular anticancer drugs. Those findings suggest combination-treatment hypotheses, not demonstrated clinical combinations.
Sam: The review also reports some experiments where normal cells were spared. Should a researcher interpret that as tumour selectivity?
Alex: As a promising observation in those specific comparisons. Some studies tested normal fibroblasts or other non-cancer cells and found no comparable impairment. But selected cell types do not establish whole-body safety. The review explicitly says safety issues still need resolving.
Sam: And blood-vessel inhibition introduces another kind of evidence. Were those experiments confined to cancer cells?
Alex: No. They included cultured blood-vessel lining cells, tissue assays, and animal models such as zebrafish. Researchers measured processes including cell migration, sprouting, and vessel formation. That supports an anti-angiogenic hypothesis, but inhibiting those processes is not itself proof that a treatment controls human cancer.
Sam: The diabetes work sounds closer to a whole-body disease outcome. Did it move beyond isolated cells?
Alex: Yes. Cafestol first showed effects on insulin secretion in a rat-derived cell line and glucose uptake in muscle cells. In mice modeling type-two diabetes, treatment for ten weeks reduced fasting glucose and improved several measures related to insulin function.
Sam: So there is a bridge from cellular effects to a disease model. What is still missing before calling this an antidiabetic treatment?
Alex: Human efficacy and safety. The review calls for clinical trials and says the mechanisms and differences between compounds remain unclear. It also describes kahweol reducing fat accumulation in cultured cells. That broadens the metabolic hypothesis without establishing a treatment for people.
Sam: There is a recurring translation problem here. The compound reaching a cultured cell is not necessarily the exposure a person gets from coffee.
Alex: The review gives a reason to be cautious about that bridge. Much of the absorbed material appears to undergo extensive metabolism, and the authors describe evidence of accumulation in the liver and digestive tract. The experiments summarized do not establish that drinking coffee reproduces the potentially beneficial laboratory exposures.
Sam: Given that gap, who should read the full review, and where should they start?
Alex: Researchers developing anti-inflammatory, cancer, or metabolic therapies should read it as a hypothesis map. Start with Raising Serum Lipid, then read the disease-specific section alongside it. For cancer, notice how prevention of chemical damage, cell killing, and blood-vessel inhibition rest on different experiments.
Sam: And for listeners who do not need that detailed map, what is the line to carry away?
Alex: These coffee compounds are research leads, not established treatments. Their experimental promise does not cancel their human lipid liability.
Sam: Keep both sides in view.